ALLO News and Press, Allogene Therapeutics Inc. From 10/08/21

Gainers: ChemoCentryx CCXI +57%, ReShape Lifesciences (NASDAQ:RSLS) +30%, Voyager Therapeutics VYGR +13%, Sundial Growers (NASDAQ:SNDL) +10%, Flora Growth (NASDAQ:FLGC) +6%. Losers: Allogene Therapeutics ALLO -42%, Cellectis CLLS -19%,&#x...

Recording the biggest intraday loss in nearly six months, Intellia Therapeutics (NTLA -10.7%) has shed all the gains made since late June when the company and its partner Regeneron (NASDAQ:REGN) showed promising in-vivo CRISPR-based genome editing data for the first time in humans. The w...

Allogene Therapeutics (NASDAQ:ALLO) down nearly a third premarket after FDA placed clinical hold on its AlloCAR T trials yesterday. The Agency's decision was based after a chromosomal abnormality was reported in ALLO-501A CAR T cells in a patient treated in the ALPHA2 study. Cellect...

On Thursday, Allogene Therapeutics Inc. ( NASDAQ:ALLO ) shares plummeted by more than 37% in the after-hours session after the US Food and Drug Administration (FDA) put on hold the clinical trial for AlloCAR T. The stock had surged 1.7% during the regular trading hours. Allo...

Testing in a Patient with Low Blood Counts Showed a Chromosomal Abnormality in ALLO-501A CAR T Cells of Unclear Clinical Significance; Patient Achieved a Partial Response to Therapy Investigation Ongoing to Further Characterize the Finding, Including Any Clinical Relevance, Evidence o...

With a list of 62 recent IPOs making entry to the Russell 2000 small-cap index after index provider FTSE Russell implemented its Q3 recalibrations, we discuss the recently-IPOd healthcare stocks joining the index. Following up on a previous article on biotech stocks in the group, in...

SOUTH SAN FRANCISCO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced the appointment of Jae Park, M.D.,...

MaxCyte has become the go-to partner for biotech companies using non-viral cell engineering, aided by its proprietary patented flow electroporation technology. The company has a scalable (licenses and SPLs) business model with recurring revenues. Milestone and royalty payments (at 100...

ODD Follows RMAT Designation Granted to ALLO-715 by the U.S. Food and Drug Administration in Multiple Myeloma Patients Phase 1 Data from the ALLO-715 UNIVERSAL Trial Demonstrated for the First Time that an Allogeneic CAR T Therapy Directed at BCMA Can Achieve Clinical Responses While ...

Allogene Therapeutics, Inc. (ALLO) Q2 2021 Earnings Conference Call August 04, 2021, 05:00 PM ET Company Participants Christine Cassiano - Chief Communications Officer David Chang - President and CEO Rafael Amado - EVP, Research and Development and CMO Eric Schmidt - CFO Conference Call Parti...